CreativeOne Wealth LLC Buys New Shares in Cencora, Inc. (NYSE:COR)

CreativeOne Wealth LLC purchased a new position in shares of Cencora, Inc. (NYSE:COR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,386 shares of the company’s stock, valued at approximately $1,212,000.

A number of other hedge funds also recently bought and sold shares of COR. New Millennium Group LLC acquired a new position in shares of Cencora during the second quarter worth $26,000. MFA Wealth Advisors LLC acquired a new position in shares of Cencora during the 2nd quarter worth about $30,000. Concord Wealth Partners purchased a new position in shares of Cencora in the 3rd quarter valued at about $30,000. LRI Investments LLC acquired a new stake in shares of Cencora during the 1st quarter worth about $31,000. Finally, SYSTM Wealth Solutions LLC purchased a new stake in Cencora during the second quarter worth approximately $36,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Performance

NYSE COR opened at $251.60 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. The business’s 50 day moving average is $234.91 and its two-hundred day moving average is $232.46. The stock has a market capitalization of $49.58 billion, a price-to-earnings ratio of 33.50, a PEG ratio of 1.66 and a beta of 0.44. Cencora, Inc. has a 12-month low of $195.83 and a 12-month high of $253.27.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a $0.55 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. This represents a $2.20 annualized dividend and a yield of 0.87%. Cencora’s dividend payout ratio is presently 29.29%.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares in the company, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last quarter, insiders sold 93,018 shares of company stock valued at $22,478,942. 15.80% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on COR. Barclays increased their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Robert W. Baird increased their target price on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Bank of America reissued a “neutral” rating and issued a $245.00 price target (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. UBS Group raised their price objective on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, Evercore ISI lifted their price target on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and a consensus price target of $271.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.